Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases Oct 7, 2021
Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS [email protected] and ASRS 2021 Annual Meeting Oct 1, 2021
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update Aug 12, 2021
Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease Jul 22, 2021